share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/11/05 21:46

Moomoo AI 已提取核心信息

Adial Pharmaceuticals announced the appointment of Vinay Shah as Chief Financial Officer, effective November 16, 2024, following Joseph Truluck's resignation. Shah brings over 25 years of pharmaceutical and healthcare financial experience, previously serving as CFO at Virpax Pharmaceuticals and Aravive Inc., where he helped raise over $150 million.Under the employment agreement, Shah will receive an annual base salary of $315,000 with a potential 30% discretionary bonus and 40,000 stock options. The three-year contract includes six months' severance for without-cause termination and twelve months' severance following a change of control.Truluck will remain with the company until November 15, 2024, and continue as a consultant through March 31, 2025. His separation agreement includes full salary through December 2024, 50% salary for Q1 2025, and $350 hourly consulting rate thereafter. The transition was not due to any disagreements regarding company operations or financial matters.
Adial Pharmaceuticals announced the appointment of Vinay Shah as Chief Financial Officer, effective November 16, 2024, following Joseph Truluck's resignation. Shah brings over 25 years of pharmaceutical and healthcare financial experience, previously serving as CFO at Virpax Pharmaceuticals and Aravive Inc., where he helped raise over $150 million.Under the employment agreement, Shah will receive an annual base salary of $315,000 with a potential 30% discretionary bonus and 40,000 stock options. The three-year contract includes six months' severance for without-cause termination and twelve months' severance following a change of control.Truluck will remain with the company until November 15, 2024, and continue as a consultant through March 31, 2025. His separation agreement includes full salary through December 2024, 50% salary for Q1 2025, and $350 hourly consulting rate thereafter. The transition was not due to any disagreements regarding company operations or financial matters.
Adial Pharmaceuticals宣布任命Vinay Shah为首席财务官,任命将于2024年11月16日生效,此前Joseph Truluck辞职。Shah在制药和医疗保健财务方面拥有超过25年的经验,曾担任Virpax Pharmaceuticals和Aravive Inc.的首席财务官,在那里他帮助筹集了超过15000万美元。根据雇佣协议,Shah将获得年薪315,000美元,并有可能获得30%的酌情奖金和40,000个期权。三年合同包括六个月的无因终止赔偿和在控制权变更后的十二个月赔偿。Truluck将在2024年11月15日之前继续留在公司,并将继续作为咨询顾问,直至2025年3月31日。他的离职协议包括2024年12月前的全额薪水、2025年第一季度的50%薪水,以及此后每小时350美元的咨询费。此项过渡并非由于与公司运营或财务问题的任何分歧。
Adial Pharmaceuticals宣布任命Vinay Shah为首席财务官,任命将于2024年11月16日生效,此前Joseph Truluck辞职。Shah在制药和医疗保健财务方面拥有超过25年的经验,曾担任Virpax Pharmaceuticals和Aravive Inc.的首席财务官,在那里他帮助筹集了超过15000万美元。根据雇佣协议,Shah将获得年薪315,000美元,并有可能获得30%的酌情奖金和40,000个期权。三年合同包括六个月的无因终止赔偿和在控制权变更后的十二个月赔偿。Truluck将在2024年11月15日之前继续留在公司,并将继续作为咨询顾问,直至2025年3月31日。他的离职协议包括2024年12月前的全额薪水、2025年第一季度的50%薪水,以及此后每小时350美元的咨询费。此项过渡并非由于与公司运营或财务问题的任何分歧。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息